Discover the latest developments in cannabis policy as the FDA makes a groundbreaking recommendation regarding its medical use. In a significant move, the FDA releases a report advocating for the reclassification of marijuana from Schedule 1 to Schedule 3, citing its legitimate medical benefits. Join us as Dr. David Berger from Wholistic ReLeaf shares insights on the implications of this recommendation, emphasizing the wealth of research supporting cannabis’s therapeutic potential. Explore the debate surrounding the current classification system and the potential impact on healthcare and patients. Stay informed about the evolving landscape of medical cannabis with this essential update.
source